AGC expands partnership with Novavax in U.S.

By The Science Advisory Board staff writers

August 11, 2020 -- AGC Biologics is expanding its relationship with Novavax by increasing manufacturing of Novavax's Matrix-M adjuvant for the COVID-19 vaccine candidate from its Seattle facility.

NVX-CoV2373 is Novavax's stable prefusion protein vaccine made using nanoparticle technology. AGC will optimize process development for scaled-up production of Matrix-M to enable Novavax to deliver a worldwide supply of the vaccine in 2020 and 2021.

AGC is already providing contract development and manufacturing organization services to Novavax for MatrixM from its facility in Copenhagen.

AGC Biologics, Molecular Partners develop COVID-19 protein therapy
AGC Biologics has partnered with clinical-stage biotechnology company Molecular Partners to create a protein therapy against SARS-CoV-2, the virus that...
AGC Biologics expands plasmid manufacturing capacity
AGC Biologics is expanding its plasmid DNA Center of Excellence in Heidelberg, Germany, to meet the need for process development and manufacturing of...
Saiba selects AGC to manufacture COVID-19 vaccine
Contract development and manufacturing organization AGC Biologics said it will be manufacturing a SARS-CoV-2 vaccine for Swiss biotechnology firm Saiba.
AGC to manufacture adjuvant for Novavax COVID-19 vaccine
AGC Biologics announced it is partnering with Novavax for large-scale good manufacturing practices production of critical components for Novavax's coronavirus...
AGC acquires commercial manufacturing facility
Contract development and manufacturing organization AGC Biologics has purchased a large-scale biopharmaceutical manufacturing facility in Boulder, CO.

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter